Search - tctmd.com

Displaying 41 - 60 of 304

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

High-Protein Diets Linked to Amino Acid Activation of ASCVD Pathway

L.A. McKeown

February 21, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Statin Use Has Plateaued in US Primary Prevention Patients

Michael O'Riordan

December 05, 2023

News Daily News

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Michael O'Riordan

November 21, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

Advertisement

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 2024 Dispatch for the CV Team

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

High Lp(a) Levels Harmful in Patients With and Without ASCVD

High-Protein Diets Linked to Amino Acid Activation of ASCVD Pathway

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Less Is More: Lp(a) Much More Atherogenic Than LDL

Top General Cardiology and CVD Prevention News of 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Statin Use Has Plateaued in US Primary Prevention Patients

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Mortality Risk Varies Among Patients With Very High LDL Levels

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content